US FDA approves GSK's drug for liver disease related itching
Tweet
Share
E-mail
FILE PHOTO: Signage is pictured in the main lobby of GSK offices in London, Britain, February 20, 2025. REUTERS/Chris J. Ratcliffe/File Photo
March 19 (Reuters) - The U.S. Food and Drug Administration approved GSK's drug for severe relentless itching caused by a type of liver disease, the company said on Thursday, making it the first treatment greenlit for the condition.
(Reporting by Sriparna Roy and Christy Santhosh in Bengaluru, Bhanvi Satija in London)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
- SpaceX reportedly signs $6.3B computing deal with Reflection AI
- FDA approves GSK and Spero's oral carbapenem antibiotic Utebzi
Create E-mail Alert Related Categories
General News, ReutersRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
